Chr. Hansen reports solid financial performance in annual results despite volatile macroeconomics

Supplier Profiles On Nutrition Insight
Chr. Hansen

Related Articles

FormattedPicture

NUTRITION & HEALTH NEWS

Enzymes manufacturer Novozymes has forecasted an outlook of between 4% to 7% for the 2023 financial year, having ended 2022 strong with 11% sales growth in Q4 despite a... Read More

FormattedPicture

BUSINESS NEWS

Chr. Hansen details the connections between the gut-brain axis and Irritable Bowel Syndrome (IBS) as well as the ability of some probiotics, like the company’s... Read More

FormattedPicture

BUSINESS NEWS

Over the last few years, the nutrition industry has been challenged to meet increasing demands in several areas. From immunity to brain and mood health and their... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

NutritionInsight looks back at the biggest industry developments of the year. From the US infant formula shortage to rising inflation, it was a year filled with... Read More

FormattedPicture

BUSINESS NEWS

Enzymes manufacturer Novozymes has agreed to buy Chr. Hansen to expand in the nutrition industry. The merger resulted in a US$12.3 billion deal, writing history as the... Read More

trans